Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis

被引:19
作者
Diallo, Jean-Simon [1 ]
Aldejmah, Abdulhadi [1 ,2 ]
Mouhim, Abdelali Filali [1 ]
Fahmy, Mona Alam [1 ]
Koumakpayi, Ismael Herve [1 ]
Sircar, Kanishka [3 ]
Begin, Louis R. [4 ]
Mes-Masson, Anne-Marie [1 ,5 ]
Saad, Fred [1 ,2 ]
机构
[1] Ctr Rech CHUM, Hop Notre Dame, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada
[2] Univ Montreal, Dept Urol, Montreal, PQ H3C 3J7, Canada
[3] McGill Univ, Ctr Hlth, Dept Pathol, Montreal, PQ H3A 2T5, Canada
[4] Hop Sacre Coeur, Serv Anatomopathol, Montreal, PQ H4J 1C5, Canada
[5] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada
关键词
androgen receptor; sub-cellular location; biochemical recurrence; prostate cancer; survival tree analysis;
D O I
10.1111/j.1464-410X.2008.07514.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
To address, by co-assessing cytoplasmic and nuclear androgen receptor (AR) expression in prostate tissues, the contribution of the AR throughout the stages of prostate cancer (PC) and its value as a marker for predicting biochemical recurrence (BCR) after radical prostatectomy (RP). Archival prostate specimens from patients who were cancer-free (43), with hormone-sensitive prostate cancer (HSPC, 62), and with androgen-independent prostate cancer (AIPC, 30) were used to construct tissue microarrays (total 135). Prostatic intraepithelial neoplasia (PIN) and non-neoplastic tissues (NA) found adjacent to HSPC were also included. Nuclear and cytoplasmic AR expression was scored by two observers using a composite scale, after immunohistochemical detection of the AR. The nuclear/cytoplasmic AR expression ratio was also calculated. Univariate Kaplan-Meier plots, and multivariate Cox and survival-tree analyses, were then used to assess the ability of the AR to predict BCR in the patients with HSPC. There was markedly greater nuclear AR staining intensity in NA than in normal prostate tissues from cancer-free patients. Cytoplasmic AR expression was highest in AIPC and markedly more than in HSPC. The nuclear/cytoplasmic AR expression ratio was highest in NA and PIN. In univariate analyses, a low nuclear AR, low cytoplasmic AR, and a high nuclear/cytoplasmic AR expression ratio were associated with BCR. Although cytoplasmic AR was an independent predictor of BCR in a Cox multivariate model (hazard ratio 2.736, 95% confidence interval 1.228-6.091, P = 0.014), survival-tree analyses suggested a complex relationship between AR expression and clinicopathological features. We propose that increased nuclear AR expression might be a precursor to PC and that cytoplasmic AR could contribute to the AIPC phenotype. The predictive ability of the AR might be closely linked to clinicopathological features.
引用
收藏
页码:1302 / 1309
页数:8
相关论文
共 51 条
[1]
Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer [J].
Amirghofran, Z ;
Monabati, A ;
Gholijani, N .
PATHOLOGY & ONCOLOGY RESEARCH, 2004, 10 (01) :37-41
[2]
Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the Brown Norway rat prostate [J].
Banerjee, PP ;
Banerjee, S ;
Brown, TR .
ENDOCRINOLOGY, 2001, 142 (09) :4066-4075
[3]
Cytochrome c oxidase subunit Vb interacts with human androgen receptor:: A potential mechanism for neurotoxicity in spinobulbar muscular atrophy [J].
Beauchemin, AMJ ;
Gottlieb, B ;
Beitel, LK ;
Elhaji, YA ;
Leonard, P ;
Trifiro, MA .
BRAIN RESEARCH BULLETIN, 2001, 56 (3-4) :285-297
[4]
The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells [J].
Bonaccorsi, L ;
Muratori, M ;
Carloni, V ;
Marchiani, S ;
Formigli, L ;
Forti, G ;
Baldi, E .
STEROIDS, 2004, 69 (8-9) :549-552
[5]
Contribution of the androgen receptor to prostate cancer predisposition and progression [J].
Buchanan, G ;
Irvine, RA ;
Coetzee, GA ;
Tilley, WD .
CANCER AND METASTASIS REVIEWS, 2001, 20 (3-4) :207-223
[6]
Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression [J].
Burd, CJ ;
Petre, CE ;
Moghadam, H ;
Wilson, EM ;
Knudsen, KE .
MOLECULAR ENDOCRINOLOGY, 2005, 19 (03) :607-620
[7]
Constitutive activation of the androgen receptor by a point mutation in the hinge region:: A new mechanism for androgen-independent growth in prostate cancer [J].
Céraline, J ;
Cruchant, MD ;
Erdmann, E ;
Erbs, P ;
Kurtz, JE ;
Duclos, B ;
Jacqmin, D ;
Chopin, D ;
Bergerat, JP .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (01) :152-157
[8]
A review of genetic polymorphisms and prostate cancer risk [J].
Coughlin, SS ;
Hall, IJ .
ANNALS OF EPIDEMIOLOGY, 2002, 12 (03) :182-196
[9]
A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].
CRAWFORD, ED ;
EISENBERGER, MA ;
MCLEOD, DG ;
SPAULDING, JT ;
BENSON, R ;
DORR, FA ;
BLUMENSTEIN, BA ;
DAVIS, MA ;
GOODMAN, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :419-424
[10]
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress? [J].
Culine, S ;
Droz, JP .
ANNALS OF ONCOLOGY, 2000, 11 (12) :1523-1530